Initial rivaroxaban dosing in patients with atrial fibrillation

BACKGROUND: Rivaroxaban is a non‐vitamin K oral anticoagulant and has been approved for prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation (AF). Current labeling recommends 20 mg once a day (q.d.) as a standard dose and a reduced dose of 15 mg q.d. in patien...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cardiol
Huvudupphovsmän: Ablefoni, Kaja, Buchholz, Alexander, Ueberham, Laura, Hilbert, Sebastian, Dagres, Nikolaos, Husser, Daniela, Hindricks, Gerhard, Bollmann, Andreas
Materialtyp: Artigo
Språk:Inglês
Publicerad: Wiley Periodicals, Inc. 2019
Ämnen:
Clinical Investigations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6788464/
https://ncbi.nlm.nih.gov/pubmed/31317562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23235
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk